propranolol has been researched along with Mouth Neoplasms in 11 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Mouth Neoplasms: Tumors or cancer of the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination treatment for mix infantile hemangiomas (IHs) using oral propranolol with topical timolol maleate was not well documented in the literature." | 9.22 | Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. ( Li, G; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2016) |
| "The aim of this study was to investigate the therapeutic results and effects of propranolol on cardiovascular parameters in infants receiving systemic propranolol for complicated infantile hemangiomas (IHs), as well as to evaluate the adverse effects of propranolol throughout the course of treatment." | 7.81 | Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. ( Cao, RY; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2015) |
| "The multistep process of oral carcinogenesis provides a biological rationale for the use of chemoprevention in individuals at increased risk of developing oral cancer." | 5.62 | Can propranolol act as a chemopreventive agent during oral carcinogenesis? An experimental animal study. ( Carrard, VC; Castilho, RM; Gaio, EJ; Nör, F; Rösing, CK; Spuldaro, TR; Wagner, VP, 2021) |
| "The combination treatment for mix infantile hemangiomas (IHs) using oral propranolol with topical timolol maleate was not well documented in the literature." | 5.22 | Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. ( Li, G; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2016) |
| " One week after starting propranolol treatment, all rats were submitted to chemical induction of oral carcinogenesis with 4-nitroquinoline-1-oxide (4NQO)." | 3.96 | Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion. ( Bernabé, DG; Biasoli, ÉR; Cecilio, HP; Furuse, C; Kayahara, GM; Miyahara, GI; Oliveira, SHP; Pereira, KM; Valente, VB, 2020) |
| "Cervicofacial segmental infantile hemangiomas (IH) may result in airway obstruction requiring use of propranolol to induce hemangioma regression and reestablish the airway." | 3.83 | Use of intravenous propranolol for control of a large cervicofacial hemangioma in a critically ill neonate. ( Fernando, SJ; Krol, A; Leitenberger, S; MacArthur, CJ; Majerus, M, 2016) |
| "The aim of this study was to investigate the therapeutic results and effects of propranolol on cardiovascular parameters in infants receiving systemic propranolol for complicated infantile hemangiomas (IHs), as well as to evaluate the adverse effects of propranolol throughout the course of treatment." | 3.81 | Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. ( Cao, RY; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2015) |
| "Propranolol (PPL) has been suggested as an option for the treatment of various types of cancer." | 1.72 | Propranolol inhibits cell viability and expression of the pro-tumorigenic proteins Akt, NF-ĸB, and VEGF in oral squamous cell carcinoma. ( Bernabé, DG; Oliveira, SHP; Shibuya, CM; Tjioe, KC, 2022) |
| "Treatment of multiple types of oral cancer cells with isoxsuprine led to the downregulation of mesenchymal cell markers that was accompanied by reduced cell motility." | 1.62 | Activation of β2-adrenergic receptor signals suppresses mesenchymal phenotypes of oral squamous cell carcinoma cells. ( Harada, H; Ishigami-Yuasa, M; Kagechika, H; Podyma-Inoue, KA; Sakakitani, S; Takahashi, K; Takayama, R; Watabe, T, 2021) |
| "The multistep process of oral carcinogenesis provides a biological rationale for the use of chemoprevention in individuals at increased risk of developing oral cancer." | 1.62 | Can propranolol act as a chemopreventive agent during oral carcinogenesis? An experimental animal study. ( Carrard, VC; Castilho, RM; Gaio, EJ; Nör, F; Rösing, CK; Spuldaro, TR; Wagner, VP, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Shibuya, CM | 1 |
| Tjioe, KC | 1 |
| Oliveira, SHP | 2 |
| Bernabé, DG | 3 |
| Bravo-Calderón, DM | 2 |
| Assao, A | 1 |
| Garcia, NG | 1 |
| Coutinho-Camillo, CM | 1 |
| Roffé, M | 1 |
| Germano, JN | 1 |
| Oliveira, DT | 2 |
| Cecilio, HP | 1 |
| Valente, VB | 1 |
| Pereira, KM | 1 |
| Kayahara, GM | 1 |
| Furuse, C | 1 |
| Biasoli, ÉR | 1 |
| Miyahara, GI | 1 |
| Sakakitani, S | 1 |
| Podyma-Inoue, KA | 1 |
| Takayama, R | 1 |
| Takahashi, K | 1 |
| Ishigami-Yuasa, M | 1 |
| Kagechika, H | 1 |
| Harada, H | 1 |
| Watabe, T | 1 |
| Wagner, VP | 1 |
| Spuldaro, TR | 1 |
| Nör, F | 1 |
| Gaio, EJ | 1 |
| Castilho, RM | 1 |
| Carrard, VC | 1 |
| Rösing, CK | 1 |
| Frost, G | 1 |
| Relic, J | 1 |
| Xu, DP | 2 |
| Cao, RY | 1 |
| Xue, L | 2 |
| Sun, NN | 2 |
| Tong, S | 2 |
| Wang, XK | 2 |
| Li, G | 1 |
| Fernando, SJ | 1 |
| Leitenberger, S | 1 |
| Majerus, M | 1 |
| Krol, A | 1 |
| MacArthur, CJ | 1 |
| Shang, ZJ | 1 |
| Liu, K | 1 |
| Liang, DF | 1 |
| Vilardi, BM | 1 |
| Oliveira, SH | 1 |
1 trial available for propranolol and Mouth Neoplasms
| Article | Year |
|---|---|
Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions.
Topics: Administration, Oral; Administration, Topical; Antineoplastic Agents; Drug Therapy, Combination; Fac | 2016 |
10 other studies available for propranolol and Mouth Neoplasms
| Article | Year |
|---|---|
Propranolol inhibits cell viability and expression of the pro-tumorigenic proteins Akt, NF-ĸB, and VEGF in oral squamous cell carcinoma.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Humans; Mouth Neoplasms; NF-kapp | 2022 |
Beta adrenergic receptor activation inhibits oral cancer migration and invasiveness.
Topics: Adrenergic beta-Antagonists; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Mouth Neoplasms; Ne | 2020 |
Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion.
Topics: 4-Nitroquinoline-1-oxide; Adrenergic beta-Antagonists; Animals; Carcinogenesis; Carcinogens; Cytokin | 2020 |
Activation of β2-adrenergic receptor signals suppresses mesenchymal phenotypes of oral squamous cell carcinoma cells.
Topics: Androgen Receptor Antagonists; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; C | 2021 |
Can propranolol act as a chemopreventive agent during oral carcinogenesis? An experimental animal study.
Topics: 4-Nitroquinoline-1-oxide; Animals; Carcinogenesis; Carcinogens; Carcinoma, Squamous Cell; Disease Mo | 2021 |
Dangers of propranolol in preterm infants.
Topics: Apnea; Bradycardia; Hemangioma; Humans; Infant; Infant, Premature; Mouth Neoplasms; Propranolol; Ski | 2013 |
Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients.
Topics: Administration, Oral; Blood Glucose; Blood Pressure; Echocardiography; Electrocardiography; Facial N | 2015 |
Use of intravenous propranolol for control of a large cervicofacial hemangioma in a critically ill neonate.
Topics: Airway Obstruction; Critical Illness; Enterocolitis, Necrotizing; Female; Hemangioma, Capillary; Hum | 2016 |
Expression of beta2-adrenergic receptor in oral squamous cell carcinoma.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agonist | 2009 |
VEGF-C expression in oral cancer by neurotransmitter-induced activation of beta-adrenergic receptors.
Topics: Adrenergic beta-Antagonists; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Mouth Neoplasms; Ne | 2013 |